1
|
Vanbergue E, Assie S, Mounaix B, Guiadeur M, Robert F, Andrieu D, Cebron N, Meyer G, Philibert A, Foucras G. Comparison between a complete preconditioning programme and conventional conduct on behaviour, health and performance of young bulls from small cow-calf herds. Animal 2024; 18:101169. [PMID: 38772080 DOI: 10.1016/j.animal.2024.101169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 04/12/2024] [Accepted: 04/12/2024] [Indexed: 05/23/2024] Open
Abstract
Bovine respiratory diseases (BRDs) have major socioeconomic impacts in the beef sector. Antimicrobials have been traditionally used to prevent the development of BRDs upon arrival in fattening units. Currently, from a "One Health and One Welfare" perspective, alternative solutions are being investigated. Preconditioning programmes that aim at reducing stress and reinforcing immune functions have been proposed to decrease BRDs incidence. In this study, we assessed the effect of a preconditioning protocol set up in nine commercial beef herds on young bulls' behaviour, health, and performance. Preconditioned bulls (PREC) were weaned indoors 50 days before departure, and progressively fed a concentrate diet supplemented with vitamins and trace elements. They also received an anthelmintic treatment, and two doses of a trivalent vaccine against respiratory pathogens at 4-week intervals. In contrast, controls (CTRL) were kept on pasture with their dams with no vaccination or particular diets. All calves were transported together to a single sorting facility to be sorted by experimental groups, origins, and BW, forming new groups before dispatch to four fattening units. At arrival, CTRL were treated with anthelmintic drugs and received one injection of the same BRDs vaccine. No intervention was performed on PREC bulls. BRD-scores were 0.73 in PREC versus 0.07 in CTRL (P = 0.01) during the preconditioning period and 0.96 in PREC versus 0.54 in CTRL (P = 0.41) after 15 days in the fattening units. Morbidity estimates were 18% in PREC versus 1% in CTRL (P < 0.001) during the preconditioning period and 32% in PREC versus 19% (P = 0.07) in CTRL after 15 days in the fattening units. Poor housing conditions during preconditioning and a different aetiology could partly explain these results. At arrival to fattening, the average daily gain (ADG) was 1 605 g for PREC versus 1 140 g (P = 0.012) for CTRL. After fattening for 180 days, differences in BW, ADG, carcass weight and conformation were inconclusive. In Europe, preconditioning programmes including vaccination must be set up coherently with good husbandry practices and with a global adaptation of batch management of the beef sector otherwise, they may be less effective than expected.
Collapse
Affiliation(s)
- E Vanbergue
- Institut de l'élevage, Monvoisin, 35910 Le Rheu, France.
| | - S Assie
- INRAE UMR BioEpAR, ONIRIS, Site Chantrerie, 44307 Nantes Cedex, France
| | - B Mounaix
- Institut de l'élevage, Monvoisin, 35910 Le Rheu, France
| | - M Guiadeur
- Institut de l'élevage, Monvoisin, 35910 Le Rheu, France
| | - F Robert
- Deltavit, CCPA, ZA du Bois de Teillay, Quartier du Haut-Bois, 35150 Janzé, France
| | - D Andrieu
- Deltavit, CCPA, ZA du Bois de Teillay, Quartier du Haut-Bois, 35150 Janzé, France
| | - N Cebron
- IHAP, Université de Toulouse, INRAE, ENVT, Toulouse, France
| | - G Meyer
- IHAP, Université de Toulouse, INRAE, ENVT, Toulouse, France
| | - A Philibert
- Institut de l'élevage, Monvoisin, 35910 Le Rheu, France
| | - G Foucras
- IHAP, Université de Toulouse, INRAE, ENVT, Toulouse, France
| |
Collapse
|
2
|
Dormegny-Jeanjean LC, Mainberger OAE, de Crespin de Billy C, Obrecht A, Danila V, Erb A, Arcay HM, Weibel S, Blanc F, Meyer G, Tomsa M, Bertschy G, Duval F, Foucher JR. Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression. Encephale 2024; 50:137-142. [PMID: 37005193 DOI: 10.1016/j.encep.2023.01.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Revised: 01/09/2023] [Accepted: 01/27/2023] [Indexed: 04/03/2023]
Abstract
INTRODUCTION Dopamine (DA) is likely to be involved in some depressive dimensions, such as anhedonia and amotivation, which account for a part of treatment-resistant forms. Monoamine oxidase inhibitors (MAOI) and direct D2 and D3 receptors agonists (D2/3r-dAG) are known to help, but we lack safety data about their combined usage. We report on safety and tolerance of the MAOI+D2r-dAG combination in a clinical series. METHOD All patients referred to our recourse center for depression between 2013 and 2021 were screened to select those who did receive the combo. Data were extracted from clinical files. RESULTS Sixteen patients of 60±17 years of age (8 women, 7 with age>65years, all suffered from treatment resistant depression, 7 with bipolar disorder) received the combo. There were no life-threatening adverse effects (AE). However, AE were reported by 14 patients (88%) most of which were mild and consisted of insomnia, nausea, nervousness, confusion, impulse control disorder and/or "sleep attacks". One patient presented a serious AE requiring a short hospitalization for confusion. Intolerance led to failure to introduce treatment in two patients (13%). The retrospective non-interventional design, the variety of molecules, and the modest sample size limited the scope of these results. CONCLUSION There was no life-threatening safety issue in combining MAOI and D2/3r-dAG, especially regarding cardiovascular side effects. The systematic screening of AE might account for their frequency, but these precluded the treatment in only two patients. Comparative studies are needed to assess the efficacy of this new combination.
Collapse
Affiliation(s)
- L C Dormegny-Jeanjean
- Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), University Hospital of Strasbourg, 67000 Strasbourg, France; CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France.
| | - O A E Mainberger
- Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), University Hospital of Strasbourg, 67000 Strasbourg, France; CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France
| | - C de Crespin de Billy
- Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), University Hospital of Strasbourg, 67000 Strasbourg, France; CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France
| | - A Obrecht
- Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), University Hospital of Strasbourg, 67000 Strasbourg, France; CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France
| | - V Danila
- Department of Psychiatry "pole 8/9", Rouffach Psychiatric Hospital, 68250 Rouffach, France
| | - A Erb
- Department of Psychiatry "pole 8/9", Rouffach Psychiatric Hospital, 68250 Rouffach, France
| | - H M Arcay
- CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France
| | - S Weibel
- Department of Psychiatry and Mental Health-University Hospital of Strasbourg, University of Strasbourg, 67000 Strasbourg, France; Inserm UMR 1114, Physiopathology and Cognitive Psychopathology of Schizophrenia, University of Strasbourg, 67000 Strasbourg, France
| | - F Blanc
- CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France; Geriatrics Department and Expert Center for Neurocognitive Disorders, University Hospital of Strasbourg, University of Strasbourg, 67000 Strasbourg, France
| | - G Meyer
- Pharmacopsy Alsace, Clinical Pharmacy Department, Établissement Public de Santé Alsace Nord, Brumath, France; Pharmacy Department, University Hospital of Strasbourg, 67000 Strasbourg, France
| | - M Tomsa
- Department of Psychiatry "pole 8/9", Rouffach Psychiatric Hospital, 68250 Rouffach, France
| | - G Bertschy
- Department of Psychiatry and Mental Health-University Hospital of Strasbourg, University of Strasbourg, 67000 Strasbourg, France; Inserm UMR 1114, Physiopathology and Cognitive Psychopathology of Schizophrenia, University of Strasbourg, 67000 Strasbourg, France
| | - F Duval
- Department of Psychiatry "pole 8/9", Rouffach Psychiatric Hospital, 68250 Rouffach, France
| | - J R Foucher
- Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), University Hospital of Strasbourg, 67000 Strasbourg, France; CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France
| |
Collapse
|
3
|
Müller A, Efeler S, Laskowski NM, Pommnitz M, Mall JW, Meyer G, Wunder R, Köhler H, Hüttl TP, de Zwaan M. Postoperative Dumping Syndrome, Health-Related Quality of Life, Anxiety, Depression, and Eating Disturbances: Results of a Longitudinal Obesity Surgery Study. Obes Facts 2024; 17:201-210. [PMID: 38320543 PMCID: PMC10987184 DOI: 10.1159/000536602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Accepted: 01/24/2024] [Indexed: 02/08/2024] Open
Abstract
INTRODUCTION Given the lack of research on the relationship of post-surgery dumping syndrome and eating disturbances, the purpose of the present longitudinal study was to investigate whether dumping after obesity surgery is associated with pre-/postoperative eating disorder symptoms or addiction-like eating beyond the type of surgery, gender, health-realted quality of life (HRQoL) and anxiety/depressive symptoms. METHODS The study included 220 patients (76% women) before (t0) and 6 months after (t1) obesity surgery (sleeve gastrectomy [n = 152], Roux-en-Y gastric bypass [n = 53], omega loop gastric bypass [n = 15]). The Sigstad Dumping Score was used to assess post-surgery dumping syndrome. Participants further answered the Eating Disorder Examination Questionnaire (EDE-Q), Yale Food Addiction Scale 2.0 (YFAS 2.0), Short-Form Health Survey (SF-12), and Hospital Anxiety and Depression Scale (HADS) at t0 and t1. RESULTS The point prevalence of symptoms suggestive of post-surgery dumping syndrome was 33%. Regression analyses indicate an association of dumping with surgical procedure (bypass), female gender, reduced HRQoL, more anxiety/depressive symptoms, and potentially with binge eating but not with eating disorder symptoms in general or with addiction-like eating. CONCLUSION The current study failed to show a close relationship between the presence of self-reported dumping syndrome and eating disorder symptoms or addiction-like eating following obesity surgery. Further studies with longer follow-up periods should make use of clinical interviews to assess psychosocial variables and of objective measures to diagnose dumping in addition to standardized self-ratings.
Collapse
Affiliation(s)
- Astrid Müller
- Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hanover, Germany
| | - Salih Efeler
- Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hanover, Germany
| | - Nora M. Laskowski
- Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hanover, Germany
- University Clinic for Psychosomatic Medicine and Psychotherapy, Medical Faculty, Campus East-Westphalia, Ruhr-University Bochum, Luebbecke, Germany
| | - Melanie Pommnitz
- Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hanover, Germany
| | - Julian W. Mall
- Department of General, Visceral, Vascular, and Bariatric Surgery, Klinikum Nordstadt, Hanover, Germany
| | - Günther Meyer
- Department of General, Visceral, and Bariatric Surgery, AMC-WolfartKlinik, Graefeling, Germany
| | - Ruth Wunder
- Department of General, Visceral, and Bariatric Surgery, DRK-Krankenhaus Clementinenhaus, Hanover, Germany
| | - Hinrich Köhler
- Department of General, Visceral, and Bariatric Surgery, Herzogin Elisabeth Hospital, Brunswick, Germany
| | - Thomas P. Hüttl
- Department of General, Visceral, and Bariatric Surgery, Dr. Lubos Kliniken Bogenhausen, Munich, Germany
| | - Martina de Zwaan
- Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hanover, Germany
| |
Collapse
|
4
|
van Dongen LJC, Leino-Kilpi H, Jónsdóttir H, Meyer G, Henriques MA, Schoonhoven L, Suhonen R, Hafsteinsdóttir TB. The experiences of doctorally prepared nurses and doctoral nursing students with being mentored in the Nurse-Lead programme: A focus group study. Nurse Educ Pract 2023; 71:103744. [PMID: 37591035 DOI: 10.1016/j.nepr.2023.103744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Revised: 06/19/2023] [Accepted: 08/09/2023] [Indexed: 08/19/2023]
Abstract
AIM to explore experiences of being mentored and the contribution of the mentoring to leadership and professional development of doctorally prepared nurses and doctoral nursing students participating in the Nurse-Lead programme. BACKGROUND Mentoring is considered important for career development of academic nurses. Doctorally prepared nurses need a wide range of professional competences to develop sustainable careers. Therefore, they may benefit from a larger network of mentors, outside their own organization, to support their professional development. Therefore, a web-based leadership and mentoring programme was developed - the Nurse Lead programme. DESIGN A descriptive study with semi-structured focus groups. METHOD Three focus groups were conducted during an on-site programme meeting in 2019 with twenty-one doctorally prepared nurses and doctoral nursing students. The interview guide included questions about mentoring relationships and meaning of mentoring for leadership and professional development. The interviews were thematically analysed. RESULTS Five themes were identified: "Preferred characteristics of mentors", "Developing trusting relationships", "Engagement of the mentors", "Becoming a proficient researcher and team leader" and "Becoming an empowered and confident professional". CONCLUSION Mentoring supported the leadership and professional development of doctorally prepared nurses and doctoral nursing students. Participants were engaged in rewarding mentoring trajectories. The results indicate that a similar approach could be followed when developing mentoring programmes in the future.
Collapse
Affiliation(s)
- L J C van Dongen
- Department of Nursing Science, University of Turku, Finland; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; CWZ Academe, Canisius Wilhelmina Ziekenhuis, the Netherlands.
| | - H Leino-Kilpi
- Department of Nursing Science, University of Turku, Finland; Turku University Hospital, Finland
| | - H Jónsdóttir
- Faculty of Nursing and Midwifery, University of Iceland, Reykjavík, Iceland; Landspítali University Hospital, Reykjavík, Iceland
| | - G Meyer
- Institute for Health and Nursing Sciences, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - M A Henriques
- Nursing Research, Innovation and Development Centre of Lisbon, Nursing School of Lisbon, Lisbon, Portugal; Instituto Saúde Ambiental da Faculdade de Medicina da Universidade de Lisboa, Portugal
| | - L Schoonhoven
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; School of Health Sciences, Faculty of Environmental and Life Sciences, University of Southampton, UK
| | - R Suhonen
- Department of Nursing Science, University of Turku, Finland; Turku University Hospital, Finland; City of Turku Welfare Services Division, Turku, Finland
| | - T B Hafsteinsdóttir
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; University of Applied Sciences, Utrecht, the Netherlands
| |
Collapse
|
5
|
Hopper L, Collins R, Forristal K, Riello M, Conotter V, Meyer G, Vugt M. 141 THE INTENSE PROJECT: IMPROVING DEMENTIA CARE THROUGH SIMULATION OF SELF-EXPERIENCE. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The EC is concerned about the growing shortage of experienced health and social care professionals to care for people with dementia. Although specialized dementia education programs have begun to appear in recent years, a lack of consistency and adequate level of knowledge of dementia to anticipate the required treatment remains across Europe. The Improving demeNtia care Through Self-Experience (INTENSE) project supports the creation of skills improvement paths for professionals across Europe that incorporate and promote successful self-experience methodologies and practices to increase knowledge and understanding of the lived experience of dementia (e.g., Virtual Dementia Tours, role plays and practices of theatre workshops).
Methods
A systematic review of self-experience tools, training and interventions was conducted. Participatory stakeholder workshops were then held in Ireland, Italy, Germany and the Netherlands to explore ways in which self-experience could be used to better understand the experience of the person with dementia and how the simulation of self-experience could be incorporated into existing (or new) training programmes. Workshop discussions were transcribed and thematically analysed along with workshop outputs to develop the INTenSE toolkit and supporting platform.
Results
An INTenSE toolkit was developed containing interactive no-tech, low-tech and high-tech approaches to simulating self-experience. Training scenarios, facilitation approaches and sustainability plans were designed and a prototype of the INTenSE Platform (website to house and support use of the toolkit) was developed. Beta versions of each will be presented.
Conclusion
INTenSE has illustrated how participatory research can strengthen cooperation and exchange of experiences between organizations working in the field of dementia care; improve social awareness of the ability of self-experience to improve dementia care; promote the integration of self-experience practices in the training of health and social care professional; and highlight the potential for self-experience simulation to be incorporated into carer training and dementia awareness education, subject to the provision of appropriate supports.
Collapse
Affiliation(s)
- L Hopper
- Dublin City University , Dublin, Ireland
| | - R Collins
- Dublin City University , Dublin, Ireland
| | | | | | | | - G Meyer
- Martin Luther University , Halle-Wittenberg, Germany
| | - M Vugt
- Maastricht University , Maastricht, Netherlands
| |
Collapse
|
6
|
Collins R, Forristal K, Hopper L, Riello M, Conotter V, Meyer G, Vugt MD. 189 IMPROVING DEMENTIA CARE THROUGH SELF-EXPERIENCE; CO-DESIGNING A SIMULATION-BASED DEMENTIA EDUCATION TOOLKIT. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Although specialised dementia education programmes have begun to appear in recent years, they lack consistency. Knowledge gaps persist, which results in a professional workforce who can struggle to anticipate the care needs of people with dementia. Self-experience or simulation practices (e.g., roleplays, virtual reality, sensory tools) are established teaching methods that can provide learning opportunities to experience aspects of illness. These innovative learning approaches can positively impact empathy, understanding, and quality of care; however, they are rarely implemented in specialised care for people with dementia. The Improving demeNtia care Through Self-Experience (INTENSE) project has co-designed a dementia simulation toolkit to educate, equip, and train professionals to better support people with dementia.
Methods
As part of the Erasmus+ INTenSE project, a series of three participatory, online workshops were conducted with people with dementia, informal caregivers, and dementia-care professionals in Ireland, Italy, Germany, and the Netherlands. The first explored the co-design of training scenarios using simulation tools to demonstrate the lived experience of dementia. The second involved the co-design of an online training platform. The third examined the sustainable implementation of INTenSE into practice. All workshops were inductively coded and analysed thematically.
Results
Recommended training scenarios demonstrate daily activities and environments that impact people with dementia using a combination of existing and newly developed simulation tools. Four themes arose from workshop discussions: 1) representation of dementia, 2) daily challenges that impact people with dementia, 3) applying a person-centred approach, and 4) implementing self-experience training. Together these were used to develop facilitation guides to support the implementation of the INTenSE simulation toolkit into practice.
Conclusion
These findings demonstrate the potential of simulating self-experience across a range of everyday scenarios as a means to increase professionals' empathy and understanding of the lived experience of dementia. Recommendations have been developed that support the use of self-experience tools in practice.
Collapse
Affiliation(s)
- R Collins
- Dublin City University , Dublin, Ireland
| | | | - L Hopper
- Dublin City University , Dublin, Ireland
| | | | | | - G Meyer
- Martin Luther University , Halle-Wittenberg, Germany
| | - MD Vugt
- Maastricht University , Maastricht, Netherlands
| |
Collapse
|
7
|
Meyer G, Rose M. Mechanocatalytic partial depolymerization of lignocellulosic feedstock towards oligomeric glycans. CHEM-ING-TECH 2022. [DOI: 10.1002/cite.202255184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- G. Meyer
- TU Darmstadt Technische Chemie 2 Alarich-Weiss-Str. 8 64287 Darmstadt Germany
| | - M. Rose
- TU Darmstadt Technische Chemie 2 Alarich-Weiss-Str. 8 64287 Darmstadt Germany
| |
Collapse
|
8
|
Förster A, Heinrich S, Meyer G, Mikolajczyk R, Lückmann S. Inanspruchnahme von Flash Glucose Monitoring zur Glukosemessung bei
Patient*innen mit insulinpflichtigem Diabetes mellitus. Das Gesundheitswesen 2022. [DOI: 10.1055/s-0042-1753650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- A Förster
- Martin-Luther Universität Halle-Wittenberg, Institut
für Gesundheits- und Pflegewissenschaft, Halle (Saale),
Deutschland
| | - S Heinrich
- AOK Sachsen-Anhalt, Magdeburg, Deutschland
| | - G Meyer
- Martin-Luther Universität Halle-Wittenberg, Institut
für Gesundheits- und Pflegewissenschaft, Halle (Saale),
Deutschland
| | - R Mikolajczyk
- Martin-Luther Universität Halle-Wittenberg, Institut
für Medizinische Biometrie, Epidemiologie und Informatik, Halle (Saale),
Deutschland
| | - S Lückmann
- Martin-Luther Universität Halle-Wittenberg, Institut
für Medizinische Biometrie, Epidemiologie und Informatik, Halle (Saale),
Deutschland
| |
Collapse
|
9
|
Halachmi S, Avitan O, Bahouth Z, Meyer G, Masarwa I, Barbara Y. Allium (R) ureteral stent: Long term results. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00090-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Javelot H, Meyer G, Becker G, Post G, Runge V, Pospieszynski P, Schneiderlin T, Armand-Branger S, Michel B, Weiner L, Faria CGF, Drapier D, Fakra E, Fossati P, Haffen E, Yrondi A, Hingray C. [Anticholinergic scales: Use in psychiatry and update of the anticholinergic impregnation scale]. Encephale 2021; 48:313-324. [PMID: 34876278 DOI: 10.1016/j.encep.2021.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Revised: 09/01/2021] [Accepted: 09/01/2021] [Indexed: 11/28/2022]
Abstract
Anticholinergic properties are well known to prescribers, notably in mental health, as a therapeutic strategy for i.e. extrapyramidal syndrome but also as a source of numerous adverse side effects. Herein, we propose a narrative literature review describing: (i) cholinergic pharmacology and anticholinergic properties; (ii) the importance of anticholinergic therapeutic properties in psychiatry; (iii) the existing anticholinergic drug scales and their usage limitations in Psychiatry and; last (iv) an update to the anticholinergic drug impregnation scale, designed for the French psychiatry practice. The anticholinergic side effects can appear both in the peripheral level (dry mouth, constipation, etc.) and in the central level (especially as cognitive deficits). Many of the so called « anticholinergic » drugs are in fact entirely or mostly antimuscarinic and act essentially as parasympathetic system antagonists. Overall, anticholinergic/antimuscarinic side effects are usually attributed to psychotropic medications: to certain antipsychotics, notably classical neuroleptics such as phenothiazine and also to tricyclic antidepressants. In practice, the impact of anticholinergic toxicity treatments is often highlighted due to their excessively prolonged use in patients on antipsychotics. Interestingly, these antipsychotic treatments are better known for their anticholinergic side effects, especially cognitive ones, with an early onset specially in elder patients and/or in the case of polymedication. In order to evaluate anticholinergic side effects, metrics known as anticholinergic burden scales were created in the last few decades. Nowadays, 13 different scales are documented and accepted by the international academic community, but only three of them are commonly used: the Anticholinergic Drug Scale (ADS), the Anticholinergic Risk Scale (ARS) and the Anticholinergic Burden Scale (ACB). All of them are based on a similar principle, consisting of grading treatments individually, and they are normally scored from 0 - no presence of side effects - to 3 - anticholinergic effects considered to be strong or very strong. Using these scales enables the calculation of the so-called "anticholinergic burden", which corresponds to the cumulative effect of using multiple medications with anticholinergic properties simultaneously. The application of anticholinergic scales to patients with psychiatric disorders has revealed that schizophrenic patients seem to be especially sensitive to anticholinergic cognitive side effects, while elder and depressed patients were more likely to show symptoms of dementia when exposed to higher anticholinergic burden. Unfortunately, these tools appear to have a low parallel reliability, and so they might induce large differences when assessing side effects predictability. In addition, the capacity of these scales to predict central adverse effects is limited due to the fact they poorly or do not differentiate, the ability of treatments to cross the blood-brain barrier. Finally, one last limitation on the validity of these scales is prescription posology is not accounted for side effects considered to be dose dependent. Recently, the MARANTE (Muscarinic Acetylcholine Receptor ANTagonist Exposure) scale has incorporated an anticholinergic burden weighting by posology. Nevertheless, this new model can be criticized, due to the limited number of medications included and due to testing a limited number of potency ranges and dosages for each treatment. Herein, we propose an update to the Anticholinergic Impregnation Scale, developed specifically for the French Psychiatry practice. The scale validation was based on an evaluation of the prescriptions correcting anticholinergic peripheral side effects (constipation, xerostomia and xeropthalmia). This indirect evaluation allowed us to show patients with an anticholinergic impregnation score higher than 5 received significantly more treatments for constipation and xerostomia. This strategy bypasses the bias of a cognitive evaluation in patients with severe mental health disorders. Moreover, the relevance of a tool developed specifically for French psychiatry is justified by the fact that some highly prescribed treatments for mental illness in France (cyamemazine and tropatemine) are strong anticholinergics, and also by the fact they are rarely included in the existing anticholinergic scales. This update of the original scale, published in 2017, includes information whether prescribed drugs cross the blood-brain barrier and thus makes possible a more accurate assessment when evaluating anticholinergic central side effects. Finally, the anticholinergic impregnation scale will soon be integrated into a prescription help software, which is currently being developed to take into consideration dose dependent adverse effects.
Collapse
Affiliation(s)
- H Javelot
- Établissement public de santé Alsace Nord, 67170 Brumath, France; Laboratoire de toxicologie et pharmacologie neuro cardiovasculaire, université de Strasbourg, 67084 Strasbourg cedex, France.
| | - G Meyer
- Établissement public de santé Alsace Nord, 67170 Brumath, France
| | - G Becker
- Laboratoire de toxicologie et pharmacologie neuro cardiovasculaire, université de Strasbourg, 67084 Strasbourg cedex, France
| | - G Post
- Centre hospitalier de Rouffach, 68250 Rouffach, France; GIP Symaris, 68250 Rouffach, France
| | - V Runge
- Laboratoire de mathématiques et modélisation d'Evry (LaMME), UEVE - université Paris-Saclay, 91037 Evry cedex, France
| | | | | | - S Armand-Branger
- ServicePharmacie, Centre de santé mentale Angevin (CESAME), 49130 Sainte-Gemmes-sur-Loire, France
| | - B Michel
- ServicePharmacie, CHU de Strasbourg, 67000 Strasbourg, France
| | - L Weiner
- Clinique de psychiatrie, CHU de Strasbourg, 67000 Strasbourg, France; Laboratoire de psychologie des cognitions, université de Strasbourg, 67000 Strasbourg, France
| | - C G F Faria
- Institute of Psychiatry, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brésil
| | - D Drapier
- Pôle hospitalo-universitaire de psychiatrie adulte, centre hospitalier Guillaume-Régnier, 35700 Rennes, France; EA 4712, comportements et noyaux gris centraux, université de Rennes 1, 35000 Rennes, France
| | - E Fakra
- Pôle universitaire de psychiatrie, CHU de Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - P Fossati
- Inserm U1127, ICM, service de psychiatrie adultes, groupe hospitalier pitié Salpêtrière, Sorbonne université, AP-HP, 75013 Paris, France
| | - E Haffen
- CIC-1431 Inserm, service de psychiatrie, CHU de Besançon, 25000 Besançon, France; Laboratoire de Neurosciences, université de Franche-Comté, 25000 Besançon, France
| | - A Yrondi
- Service de Psychiatrie et de Psychologie Médicale, CHU de Toulouse, Hôpital Purpan, 31059 Toulouse, France; Centre Expert Dépression Résistante FondaMental, CHU de Toulouse, Hôpital Purpan, 31059 Toulouse, France; ToNIC Toulouse NeuroImaging Centre, Université de Toulouse, INSERM, UPS, 31024 Toulouse, France
| | - C Hingray
- Pôle hospitalo-universitaire de psychiatrie d'adultes du Grand Nancy, Centre psychothérapique de Nancy, 54520 Laxou, France; Département de neurologie, CHU de Nancy, 54000 Nancy, France
| |
Collapse
|
11
|
Javelot H, Straczek C, Meyer G, Gitahy Falcao Faria C, Weiner L, Drapier D, Fakra E, Fossati P, Weibel S, Dizet S, Langrée B, Masson M, Gaillard R, Leboyer M, Llorca PM, Hingray C, Haffen E, Yrondi A. Psychotropics and COVID-19: An analysis of safety and prophylaxis. Encephale 2021; 47:564-588. [PMID: 34548153 PMCID: PMC8410507 DOI: 10.1016/j.encep.2021.08.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Accepted: 08/19/2021] [Indexed: 12/15/2022]
Abstract
The use of psychotropics during the COVID-19 pandemic has raised two questions, in order of importance: first, what changes should be made to pharmacological treatments prescribed to mental health patients? Secondly, are there any positive side effects of these substances against SARS-CoV-2? Our aim was to analyze usage safety of psychotropics during COVID-19; therefore, herein, we have studied: (i) the risk of symptomatic complications of COVID-19 associated with the use of these drugs, notably central nervous system activity depression, QTc interval enlargement and infectious and thromboembolic complications; (ii) the risk of mistaking the iatrogenic impact of psychotropics with COVID-19 symptoms, causing diagnostic error. Moreover, we provided a summary of the different information available today for these risks, categorized by mental health disorder, for the following: schizophrenia, bipolar disorder, anxiety disorder, ADHD, sleep disorders and suicidal risk. The matter of psychoactive substance use during the pandemic is also analyzed in this paper, and guideline websites and publications for psychotropic treatments in the context of COVID-19 are referenced during the text, so that changes on those guidelines and eventual interaction between psychotropics and COVID-19 treatment medication can be reported and studied. Finally, we also provide a literature review of the latest known antiviral properties of psychotropics against SARS-CoV-2 as complementary information.
Collapse
Affiliation(s)
- H Javelot
- Établissement public de santé Alsace Nord, 141, avenue Strasbourg, 67170 Brumath, France; Laboratoire de toxicologie et pharmacologie neuro cardiovasculaire, centre de recherche en biomédecine de Strasbourg, université de Strasbourg, 1, rue Eugène-Boeckel, 67000 Strasbourg, France.
| | - C Straczek
- Département de pharmacie, CHU d'Henri-Mondor, université Paris Est Créteil (UPEC), AP-HP, 1, rue Gustave-Eiffel, 94000 Créteil, France; Inserm U955, institut Mondor de recherche biomédical, neuropsychiatrie translationnelle, 8, rue du Général-Sarrail, 94000 Créteil, France
| | - G Meyer
- Service pharmacie, établissement public de santé Alsace Nord, 141, avenue Strasbourg, 67170 Brumath, France; Service pharmacie, CHU de Strasbourg, 1, porte de L'Hôpital, 67000 Strasbourg, France
| | - C Gitahy Falcao Faria
- Institute of Psychiatry, Federal University of Rio de Janeiro (UFRJ), avenue Pedro-Calmon, 550 - Cidade Universitária da Universidade Federal do Rio de Janeiro, 21941-901 Rio de Janeiro, Brazil
| | - L Weiner
- Clinique de psychiatrie, hôpitaux universitaire de Strasbourg, 1, porte de L'Hôpital, 67000 Strasbourg, France
| | - D Drapier
- Pôle hospitalo-universitaire de psychiatrie adulte, centre hospitalier Guillaume-Régnier, rue du Moulin-de-Joué, 35700 Rennes, France; EA 4712, comportements et noyaux gris centraux, université de Rennes 1, 2, avenue du Professeur Léon-Bernard, CS 34317, campus santé de Villejean, 35043 Rennes cedex, France
| | - E Fakra
- Pôle universitaire de psychiatrie, CHU de Saint-Étienne, 37, rue Michelet, 42000 Saint-Étienne, France
| | - P Fossati
- Inserm U1127, ICM, service de psychiatrie adultes, groupe hospitalier pitié Salpêtrière, Sorbonne université, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - S Weibel
- Clinique de psychiatrie, hôpitaux universitaire de Strasbourg, 1, porte de L'Hôpital, 67000 Strasbourg, France
| | - S Dizet
- Centre de ressources et d'expertise en psychopharmacologie (CREPP) Bourgogne Franche-Comté, Chalon-sur-Saône, France; Service Pharmacie, CHS de Sevrey, 55, rue Auguste-Champio, 71100 Sevrey, France
| | - B Langrée
- Service pharmacie, centre hospitalier Guillaume-Régnier, rue du Moulin-de-Joué, 35700 Rennes, France; Clinique du Château de Garches, Nightingale Hospitals-Paris, 11, bis rue de la Porte-Jaune, 92380 Garches, France
| | - M Masson
- SHU, GHU psychiatrie et neurosciences, 1, rue Cabanis, 75014 Paris, France; GHU psychiatrie et neurosciences, université de Paris, Paris, France
| | - R Gaillard
- Conseil national des universités (CNU), 1, rue Cabanis, 75014 Paris, France
| | - M Leboyer
- Inserm, DMU IMPACT, IMRB, translational neuropsychiatry, fondation FondaMental, hôpitaux universitaires « H. Mondor », université Paris Est Créteil (UPEC), AP-HP, 40, rue de Mesly, 94000 Créteil, France; CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - P M Llorca
- Université Clermont-Auvergne, 1, rue Lucie- et Raymond-Aubrac, 63100 Clermont-Ferrand, France; Pôle hospitalo-universitaire de psychiatrie d'adultes du Grand Nancy, centre psychothérapique de Nancy, 1, rue Docteur Archambault, 54520 Laxou, France
| | - C Hingray
- Département de neurologie, CHU de Nancy, 25, rue Lionnois, 54000 Nancy, France; CIC-1431 Inserm, service de psychiatrie, CHU de Besançon, 3, boulevard Alexandre-Fleming, 25000 Besançon, France
| | - E Haffen
- Laboratoire de neurosciences, université de Franche-Comté, 19, rue Ambroise-Paré, 25030 Besançon cedex, France
| | - A Yrondi
- Unité ToNIC, UMR 1214 CHU Purpan-Pavillon Baudot, place du Dr Joseph Baylac, 31024 Toulouse cedex 3, France
| |
Collapse
|
12
|
Nguyen N, Thalhammer R, Skudlik S, Müller M, Meyer G, Beutner K. PECAN- ein Konzept zur Förderung der sozialen Teilhabe und Aktivität von Pflegeheimbewohner*innen mit Kontrakturen: eine cluster-randomisierte kontrollierte Studie. Das Gesundheitswesen 2021. [DOI: 10.1055/s-0041-1732164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- N Nguyen
- Institut für Gesundheits- und Pflegewissenschaft, Martin-Luther-Universität Halle-Wittenberg
| | - R Thalhammer
- Fakultät für Angewandte Gesundheits- und Sozialwissenschaften, Technische Hochschule Rosenheim
| | - S Skudlik
- Fakultät für Angewandte Gesundheits- und Sozialwissenschaften, Technische Hochschule Rosenheim
| | - M Müller
- Fakultät für Angewandte Gesundheits- und Sozialwissenschaften, Technische Hochschule Rosenheim
| | - G Meyer
- Institut für Gesundheits- und Pflegewissenschaft, Martin-Luther-Universität Halle-Wittenberg
| | - K Beutner
- Institut für Gesundheits- und Pflegewissenschaft, Martin-Luther-Universität Halle-Wittenberg
| |
Collapse
|
13
|
Réau V, Terrier B, Ackermann F, Killian M, Hamidou M, Meyer G, Osorio-Perez F, Rohmer J, Lefèvre G, Kahn J, Groh M. Présentation clinique et facteurs de risque de rechute au cours des thromboses veineuses associées à une hyperéosinophilie : étude multicentrique rétrospective à propos de 54 patients. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.03.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Battault S, Risdon S, Bouvet R, Sigaudo-Roussel D, De Santa Barbara P, Briand L, Roustit M, Meyer G, Walther G. Sucralose and Acesulfame K modulate human and rodent vascular smooth muscle contractility independently of the presence of the sweet taste receptor. A study of the SOSweet project. Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2021.04.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Sanchez O, Benhamou Y, Bertoletti L, Constans J, Couturaud F, Delluc A, Elias A, Fischer AM, Frappé P, Gendron N, Girard P, Godier A, Gut-Gobert C, Laporte S, Mahé I, Mauge L, Meneveau N, Meyer G, Mismetti P, Parent F, Pernod G, Quéré I, Revel MP, Roy PM, Salaün PY, Smadja DM, Sevestre MA. [Recommendations for best practice in the management of venous thromboembolic disease in adults. Long version]. Rev Mal Respir 2021; 38 Suppl 1:e1-e6. [PMID: 31280989 DOI: 10.1016/j.rmr.2019.05.038] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- O Sanchez
- Université de Paris, Service de pneumologie et soins intensifs, AH-HP, hôpital Européen Georges-Pompidou, 75015 Paris, France; F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France.
| | - Y Benhamou
- Service de médecine interne, Normandie université UNI Rouen U1096, CHU Charles-Nicolle, 76000 Rouen, France
| | - L Bertoletti
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Inserm UMR1059, Inserm, CIC-1408, équipe dysfonction vasculaire et hémostase, service de médecine vasculaire et thérapeutique, CHU de Saint-Étienne, université Jean-Monnet, 42000 Saint-Étienne, France
| | - J Constans
- Service de médecine vasculaire, hôpital Saint-André, université de Bordeaux, 33000 Bordeaux, France
| | - F Couturaud
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Département de médecine interne et pneumologie, EA3878-GETBO, CIC Inserm1412, université de Bretagne occidentale, centre hospitalo-universitaire de Brest, 29200 Brest, France
| | - A Delluc
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; EA 3878 GETBO, université de Bretagne occidentale, 29200 Brest, France
| | - A Elias
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Département de médecine vasculaire, hôpital Sainte-Musse, 83100 Toulon, France
| | - A-M Fischer
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Service d'hématologie biologique hôpital européen Georges-Pompidou, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, 75015 Paris, France
| | - P Frappé
- Inserm UMR 1059 Sainbiose DVH, Inserm CIC-EC 1408, département de médecine générale, université de Saint-Étienne, 42000 Saint-Étienne, France
| | - N Gendron
- Inserm UMR 1148, laboratoire d'hématologie, hôpital Bichat-Claude-Bernard, université Paris Diderot, Sorbonne Paris Cité, AP-HP, 75018 Paris, France
| | - P Girard
- Institut du Thorax-Curie-Montsouris, l'institut Mutualiste Montsouris, 75014 Paris, France
| | - A Godier
- Inserm UMR-S 1140, service d'anesthésie réanimation, hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France
| | - C Gut-Gobert
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Département de médecine interne et pneumologie, EA3878-GETBO, CIC Inserm1412, université de Bretagne occidentale, centre hospitalo-universitaire de Brest, 29200 Brest, France
| | - S Laporte
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Inserm, unité de recherche clinique, SAINBOIS U1059 équipe DVH, hôpital Nord, université Jean-Monnet, université de Lyon, innovation, pharmacologie, CHU Saint-Étienne, 42000 Saint-Étienne, France
| | - I Mahé
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Service de médecine interne, hôpital Louis-Mourier, université Paris 7, Assistance publique-Hôpitaux de Paris, 92700 Colombes, France; Inserm UMR S1140, 75006 Paris, France
| | - L Mauge
- UMR-S 970, Paris-Cardiovascular Research Center (PARCC), service d'hématologie biologique, hôpital européen Georges-Pompidou, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, 75015 Paris, France
| | - N Meneveau
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Service de cardiologie, EA3920, université de Bourgogne-Franche Comté, CHU Jean-Minjoz, boulevard Fleming, 25030 Besançon cedex, France
| | - G Meyer
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Université de Paris, Service de pneumologie et soins intensifs, AH-HP, Hôpital Européen Georges Pompidou, 75015 Paris, France; Inserm UMRS 970, 75015 Paris, France; Inserm CIC 1418, 75015 Paris, France
| | - P Mismetti
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Inserm, SAINBOIS U1059 équipe DVH, unité de recherche clinique, innovation, pharmacologie, service de médecine vasculaire et thérapeutique, hôpital Nord, université Jean-Monnet, université de Lyon, CHU Saint-Étienne, 42000 Saint-Étienne, France
| | - F Parent
- Service de pneumologie, centre de référence de l'hypertension pulmonaire, hôpital Bicêtre, faculté de médecine, université Paris-Sud, université Paris-Saclay, AP-HP, 94270 Le Kremlin-Bicêtre, France; Inserm UMR-S 999, hôpital Marie-Lannelongue, 92350 Le Plessis-Robinson, France
| | - G Pernod
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Service universitaire de médecine vasculaire, CNRS, TIMC-IMAG UMR-5525, Thèmas, CHU Grenoble, université Grenoble Alpes, 38700 La Tronche, France
| | - I Quéré
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Département de médecine vasculaire, centre de référence des maladies vasculaires rares, EA2992, université de Montpellier, hôpital Saint-Éloi, CHU de Montpellier, 34295 Montpellier cedex 5, France
| | - M-P Revel
- Service de radiologie A, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, 75014 Paris, France
| | - P-M Roy
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Département de médecine d'urgence et service de médecine vasculaire, CHU d'Angers, 49000 Angers, France; Institut Mitovasc, UMR 1083, UFR santé, université d'Angers, 49000 Angers, France
| | - P-Y Salaün
- Inserm EA3878 (GETBO), service de médecine nucléaire, université de Bretagne occidentale, CHRU de Brest, 29200 Brest, France
| | - D M Smadja
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Unversité de Paris, Service d'hématologie, AH-HP, Hôpital Européen Georges-Pompidou, 75015 Paris, France; Laboratoire de recherche biochirurgicale, fondation Carpentier, Innovations Thérapeutiques en Hémostase, INSERM UMRS 1140, 75006 Paris, France
| | - M-A Sevestre
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Service de médecine vasculaire, EA 7516 Chimère, CHU d'Amiens, 80080 Amiens, France
| |
Collapse
|
16
|
Mahé I, Meyer G, Girard P, Bertoletti L, Laporte S, Couturaud F, Mismetti P, Sanchez O. [Treatment of cancer associated thrombosis. 2019 update of the French guidelines]. Rev Mal Respir 2021; 38:427-437. [PMID: 33858733 DOI: 10.1016/j.rmr.2021.03.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2020] [Accepted: 01/11/2021] [Indexed: 11/28/2022]
Affiliation(s)
- I Mahé
- Service de Médecine Interne-Hôpital Louis Mourier, Assistance publique des Hôpitaux de Paris, Colombes, Université de Paris, Inserm UMR_S1140, Paris, F-CRIN INNOVTE, St-Etienne, France
| | - G Meyer
- Service de Pneumologie et de soins intensifs, Hôpital Européen Georges-Pompidou, Assistance publique des Hôpitaux de Paris, Inserm UMRS 970, Université de Paris, Inserm CIC 1418, Paris, F-CRIN INNOVTE, St-Etienne, France
| | - P Girard
- Institut du Thorax Curie-Montsouris, l'Institut mutualiste Montsouris, Paris, F-CRIN INNOVTE, St-Etienne, France
| | - L Bertoletti
- Service de Médecine Vasculaire et Thérapeutique, CHU de St-Etienne, Inserm UMR1059, Equipe Dysfonction Vasculaire et Hémostase, Université Jean-Monnet, Saint-Etienne, Inserm, CIC-1408, Saint-Etienne, F-CRIN INNOVTE, Saint-Etienne, France
| | - S Laporte
- SAINBOIS U1059 équipe DVH, Université Jean-Monnet, Université de Lyon, Inserm, Unité de recherche clinique, Innovation, Pharmacologie, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne, F-CRIN INNOVTE, St-Etienne, France
| | - F Couturaud
- Département de médecine interne et pneumologie, EA3878-GETBO, CIC_INSERM1412, université de Bretagne occidentale, centre hospitalo-universitaire de Brest, F-CRIN INNOVTE, St-Etienne, France
| | - P Mismetti
- Service de Médecine Vasculaire et Thérapeutique, CHU de St-Etienne, Inserm UMR1059, Equipe Dysfonction Vasculaire et Hémostase, Université Jean-Monnet, Saint-Etienne, Inserm, CIC-1408, Saint-Etienne, F-CRIN INNOVTE, Saint-Etienne, France
| | - O Sanchez
- Service de Pneumologie et de soins intensifs, Hôpital européen Georges-Pompidou, Assistance publique des Hôpitaux de Paris, Université de Paris, Inserm UMRS 1140, Paris, F-CRIN INNOVTE, St-Etienne, France.
| |
Collapse
|
17
|
Bintein F, Yannoutsos A, Chatellier G, Fontaine M, Damotte D, Paterlini-Bréchot P, Meyer G, Duchatelle V, Marini V, Schwering KL, Labrousse C, Beaussier H, Zins M, Salmeron S, Lajonchère JP, Priollet P, Emmerich J, Trédaniel J. Patients with atherosclerotic peripheral arterial disease have a high risk of lung cancer: Systematic review and meta-analysis of literature. J Med Vasc 2021; 46:53-65. [PMID: 33752847 DOI: 10.1016/j.jdmv.2020.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Accepted: 12/23/2020] [Indexed: 12/24/2022]
Abstract
PURPOSE Lung cancer and atherosclerosis share common risk factors. Literature data suggest that the prevalence of lung malignancy in patients with peripheral arterial disease (PAD) is higher than in the general population. Our goal was to determine, through a systematic literature review, the prevalence of lung cancer in patients with PAD. METHODS We consulted available publications in the Cochrane library, MEDLINE, PUBMED, EMBASE, and ClinicalTrials.gov. We included all articles, written in English or French, published between 1990 and 2020 reporting the prevalence of lung cancer in patients with PAD (atherosclerotic aortic aneurysm or peripheral occlusive diseases). Patients with coronary artery disease, cardiac valvulopathy or carotid stenosis were not included. We did not include case reports. We performed a critical analysis of each article. Data were collected from two independent readers. A fixed effect model meta-analysis allowed to estimate a summary prevalence rate. RESULTS We identified 303 articles, and selected 19 articles according to selection criteria. A total of 16849 patients were included (mean age 68.3 years, 75.1% of males). Aortic aneurysms were found in 29% of patients and atherosclerotic occlusive disease in 66% of patients. Lung cancer was identified in 538 patients, representing a prevalence of 3%. DISCUSSION Lung cancer is found in 3% of patients with atherosclerotic PAD. This prevalence is higher than that found in lung cancer screening programs performed in the general population of smokers and former smokers. These patients should be screened for lung cancer. Their selection may dramatically increase the benefit of lung cancer screening.
Collapse
Affiliation(s)
- F Bintein
- Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France.
| | - A Yannoutsos
- Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France; Inserm UMR 1153 Center of Research in Epidemiology and Statistics, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - G Chatellier
- Hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | | | - D Damotte
- Hôpital Cochin, AP-HP, 75014 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Unité Inserm U1138, centre de recherche des Cordeliers, Paris, France
| | | | - G Meyer
- Hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - V Duchatelle
- Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France
| | - V Marini
- Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France
| | | | - C Labrousse
- Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France
| | - H Beaussier
- Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France
| | - M Zins
- Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France
| | - S Salmeron
- Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France
| | - J-P Lajonchère
- Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France
| | - P Priollet
- Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France
| | - J Emmerich
- Groupe hospitalier Paris Saint-Joseph, 75014 Paris, France; Inserm UMR 1153 Center of Research in Epidemiology and Statistics, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - J Trédaniel
- Hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Unité Inserm UMR-S 1124, toxicologie, pharmacologie et signalisation cellulaire, Paris, France
| |
Collapse
|
18
|
Cohen Aubart F, Lhote R, Hertig A, Noel N, Costedoat-Chalumeau N, Cariou A, Meyer G, Cymbalista F, de Prost N, Pottier P, Joly L, Lambotte O, Renaud MC, Badoual C, Braun M, Palombi O, Duguet A, Roux D. Progressive clinical case-based multiple-choice questions: An innovative way to evaluate and rank undergraduate medical students. Rev Med Interne 2021; 42:302-309. [PMID: 33518414 DOI: 10.1016/j.revmed.2020.11.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Revised: 10/04/2020] [Accepted: 11/10/2020] [Indexed: 11/28/2022]
Abstract
INTRODUCTION In France, at the end of the sixth year of medical studies, students take a national ranking examination including progressive clinical case-based multiple-choice questions (MCQs). We aimed to evaluate the ability of these MCQs for testing higher-order thinking more than knowledge recall, and to identify their characteristics associated with success and discrimination. METHODS We analysed the 72 progressive clinical cases taken by the students in the years 2016-2019, through an online platform. RESULTS A total of 72 progressive clinical cases (18 for each of the 4 studied years), corresponding to 1059 questions, were analysed. Most of the clinical cases (n=43, 60%) had 15 questions. Clinical questions represented 89% of all questions, whereas basic sciences questions accounted for 9%. The most frequent medical subspecialties were internal medicine (n=90, 8%) and infectious diseases (n=88, 8%). The most frequent question types concerned therapeutics (26%), exams (19%), diagnosis (14%), and semiology (13%). Level 2 questions ("understand and apply") accounted for 59% of all questions according to the Bloom's taxonomy. The level of Bloom's taxonomy significantly changed over time with a decreasing number of level 1 questions ("remember") (P=0.04). We also analysed the results of the students among 853 questions of training ECNi. Success and discrimination significantly decreased when the number of correct answers increased (P<0.0001 both). The success, discrimination, mean score, and mean number of discrepancies did not differ according to the diagnosis, exam, imaging, semiology, or therapeutic type of questions. CONCLUSION Progressive clinical case-based MCQs represent an innovative way to evaluate undergraduate students.
Collapse
Affiliation(s)
- F Cohen Aubart
- Service de médecine interne 2, hôpital Pitié-Salpêtrière, centre national de référence maladies systémiques rares et histiocytoses, Sorbonne université, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
| | - R Lhote
- Service de médecine interne 2, hôpital Pitié-Salpêtrière, centre national de référence maladies systémiques rares et histiocytoses, Sorbonne université, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - A Hertig
- Service de transplantation rénale, hôpital Pitié-Salpêtrière, Sorbonne université, Assistance publique-Hôpitaux de Paris, 75013 Paris, France
| | - N Noel
- Service de médecine interne, hôpital du Kremlin-Bicêtre, Assistance publique-Hôpitaux de Paris, 94250 Le Kremlin Bicêtre, France
| | - N Costedoat-Chalumeau
- Département de médecine interne, hôpital Cochin, Assistance publique-Hôpitaux de Paris, centre de référence maladies autoimmunes et systémiques rares, université de Paris, Cress, Inserm, INRA, 75014 Paris, France
| | - A Cariou
- Service de médecine intensive et réanimation, hôpital Cochin, Assistance publique-Hôpitaux de Paris, centre-université de Paris, 75014 Paris, France
| | - G Meyer
- Service de pneumologie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 75015 Paris, France
| | - F Cymbalista
- Service d'hématologie, hôpital Avicenne, Assistance publique-Hôpitaux de Paris, 93000 Bobigny, France
| | - N de Prost
- Service de réanimation médicale, hôpitaux universitaires Henri-Mondor, Assistance publique-Hôpitaux de Paris, groupe de recherche clinique CARMAS, université Paris Est-Créteil, 94000 Créteil, France
| | - P Pottier
- Service de médecine interne, CHU de Nantes, université de Nantes, site Hôtel Dieu, 44000 Nantes, France
| | - L Joly
- Service de gériatrie, hôpitaux de Brabois, université de Lorraine, CHRU de Nancy, 54500 Vandoeuvre Les Nancy, France
| | - O Lambotte
- Service de médecine interne, hôpital du Kremlin-Bicêtre, Assistance publique-Hôpitaux de Paris, 94250 Le Kremlin Bicêtre, France
| | - M-C Renaud
- Faculté de médecine, Sorbonne université, 75013 Paris, France
| | - C Badoual
- Service d'anatomopathologie, hôpital européen Georges-Pompidou, université de Paris, 75015 Paris, France
| | - M Braun
- Service de neuroradiologie, CHRU de Nancy, université de Lorraine, 54500 Nancy, France
| | - O Palombi
- Service de neurochirurgie, CHU de Grenoble, université Grenoble Alpes, 38000 Grenoble, France
| | - A Duguet
- Service de pneumologie, hôpital Pitié-Salpêtrière, Sorbonne université, Assistance publique-Hôpitaux de Paris, 75013 Paris, France
| | - D Roux
- Service de médecine intensive réanimation, hôpital Louis-Mourier, université de Paris, Assistance publique-Hôpitaux de Paris, 92700 Colombes, France; Inserm, IAME, UMR-1137, 75018 Paris, France
| |
Collapse
|
19
|
Javelot H, Samalin L, Weiner L, Meyer G, Fossati P, Haffen E, Llorca PM. [Psychopharmacotherapeutic guidelines : a challenge during health crisis]. Rev Med Liege 2020; 75:159-160. [PMID: 33211440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The construction of pharmacological guidelines is a complex endeavor, and this is all the truer amidst a health crisis such as the current SARS-CoV-2 pandemic. In psychiatric settings, guidelines have to consider the handling of other drugs (i.e., psychotropic medications), that have been suggested as potentially prophylactic for COVID-19. These dialectics are discussed here, and the methodological foundations used for the elaboration of guidelines are put forward.
Collapse
Affiliation(s)
- H Javelot
- Etablissement Public de Santé Alsace Nord, Brumath, France; Laboratoire de Toxicologie et Pharmacologie Neurocardiovasculaire, Université de Strasbourg, France
| | - L Samalin
- CHU Clermont-Ferrand, France; Université Clermont Auvergne, France
| | - L Weiner
- Clinique de Psychiatrie, CHU Strasbourg; Laboratoire de Psychologie des Cognitions, Université de Strasbourg, France
| | - G Meyer
- Service Pharmacie, Etablissement Public de Santé Alsace Nord, Brumath, France; Service Pharmacie, CHU Strasbourg, France
| | - P Fossati
- Service de Psychiatrie adultes, APHP, Sorbonne Université, Groupe Hospitalier pitié Salpêtrière, ICM, Paris, France
| | - E Haffen
- Service de Psychiatrie, CHU Besançon, France; Laboratoire de Neurosciences, Université de Franche-Comté, Besançon, France
| | - P M Llorca
- CHU Clermont-Ferrand, France; Université Clermont Auvergne, France
| |
Collapse
|
20
|
Khamisse E, Dunoyer C, Ar Gouilh M, Brown P, Meurens F, Meyer G, Monchatre-Leroy E, Pavio N, Simon G, Le Poder S. Opinion paper: Severe Acute Respiratory Syndrome Coronavirus 2 and domestic animals: what relation? Animal 2020; 14:2221-2224. [PMID: 32638677 PMCID: PMC7308594 DOI: 10.1017/s1751731120001639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Affiliation(s)
- E Khamisse
- Direction de l'évaluation des risques, ANSES, 94700Maisons-Alfort, France
| | - C Dunoyer
- Direction de l'évaluation des risques, ANSES, 94700Maisons-Alfort, France
| | - M Ar Gouilh
- Groupe de Recherche sur l'Adaptation Microbienne, Normandie Université, 14000Caen, France
- Service de Virologie, CHU de Caen, 14000Caen, France
| | - P Brown
- Laboratoire de Ploufragan-Plouzané-Niort, ANSES, 22440Ploufragan, France
| | - F Meurens
- BIOEPAR, Oniris, INRAE, 44307Nantes, France
| | - G Meyer
- ENVT, INRAE, 31076Toulouse, France
| | - E Monchatre-Leroy
- Laboratoire de la rage et de la faune sauvage, ANSES, 54220Malzéville, France
| | - N Pavio
- UMR Virologie, ENVA, INRAE, ANSES Laboratoire de santé animale, 94700Maisons-Alfort, France
| | - G Simon
- Laboratoire de Ploufragan-Plouzané-Niort, ANSES, 22440Ploufragan, France
| | - S Le Poder
- UMR Virologie, ENVA, INRAE, ANSES Laboratoire de santé animale, 94700Maisons-Alfort, France
| |
Collapse
|
21
|
Risdon S, Paillargue M, Meyer G, Walther G. Non-nutritive sweetener sucralose chronic consumption is able to reduce the deleterious effect of high-fat diet on body composition, glucose metabolism and vascular function in C57BL/6JR mice. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2020.03.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
22
|
Bolea G, Philouze C, Risdon S, Dubois M, Humberclaude A, Ginies C, Geny B, Arnaud C, Dufour C, Meyer G. n-6 Polyunsaturated fatty acid oxidation increase oxidative stress, endothelial dysfunction and atherosclerosis in ApoE mice fed with chronic Western diet. Prevention strategy by apple polyphenols. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2020.03.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Javelot H, Llorca PM, Meyer G, Fossati P, Haffen E. [Challenges for psychotropics in the context of the SARS-Cov-2 pandemic]. Encephale 2020; 46:S116-S118. [PMID: 32360037 PMCID: PMC7177137 DOI: 10.1016/j.encep.2020.04.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Accepted: 04/20/2020] [Indexed: 01/08/2023]
Abstract
French recommendations have been proposed for psychotropics use and possible adaptations during the SARS-CoV-2 epidemic. Between uncertainties linked to the lack of data and speculations about possible benefits of psychotropics against the coronavirus, we propose here elements allowing to base the pharmacotherapeutic decisions potentially useful in Covid+ patients with psychiatric disorders.
Collapse
Affiliation(s)
- H Javelot
- Établissement Public de Santé Alsace Nord, Brumath, France; Laboratoire de Toxicologie et Pharmacologie Neuro Cardiovasculaire, Université de Strasbourg, Strasbourg, France.
| | - P-M Llorca
- CHU Clermont-Ferrand, EA 7280, Université Clermont Auvergne, France
| | - G Meyer
- Service Pharmacie, Établissement Public de Santé Alsace Nord, Brumath, France; Service Pharmacie, CHU de Strasbourg, Strasbourg, France
| | - P Fossati
- Service de psychiatrie adultes, APHP, Sorbonne université, Groupe Hospitalier Pitié Salpêtrière, ICM, Inserm U1127, Paris, France
| | - E Haffen
- Service de psychiatrie, CIC-1431 Inserm, CHU de Besançon, Laboratoire de Neurosciences, Université de Franche-Comté, Besançon, France
| |
Collapse
|
24
|
Javelot H, Llorca PM, Drapier D, Fakra E, Hingray C, Meyer G, Dizet S, Egron A, Straczek C, Roser M, Masson M, Gaillard R, Fossati P, Haffen E. [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic]. Encephale 2020; 46:S14-S34. [PMID: 32376004 PMCID: PMC7196532 DOI: 10.1016/j.encep.2020.04.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Accepted: 04/17/2020] [Indexed: 12/11/2022]
Abstract
The 2019-20 coronavirus pandemic (SARS-CoV-2; severe acute respiratory syndrome coronavirus 2) has dramatic consequences on populations in terms of morbidity and mortality and in social terms, the general confinement of almost half of the world's population being a situation unprecedented in history, which is difficult today to measure the impact at the individual and collective levels. More specifically, it affects people with various risk factors, which are more frequent in patients suffering from psychiatric disorders. Psychiatrists need to know: (i) how to identify, the risks associated with the prescription of psychotropic drugs and which can prove to be counterproductive in their association with COVID-19 (coronavirus disease 2019), (ii) how to assess in terms of benefit/risk ratio, the implication of any hasty and brutal modification on psychotropic drugs that can induce confusion for a differential diagnosis with the evolution of COVID-19. We carried out a review of the literature aimed at assessing the specific benefit/risk ratio of psychotropic treatments in patients suffering from COVID-19. Clinically, symptoms suggestive of COVID-19 (fever, cough, dyspnea, digestive signs) can be caused by various psychotropic drugs and require vigilance to avoid false negatives and false positives. In infected patients, psychotropic drugs should be used with caution, especially in the elderly, considering the pulmonary risk. Lithium and Clozapine, which are the reference drugs in bipolar disorder and resistant schizophrenia, warrant specific attention. For these two treatments the possibility of a reduction in the dosage - in case of minimal infectious signs and in a situation, which does not allow rapid control - should ideally be considered taking into account the clinical response (even biological; plasma concentrations) observed in the face of previous dose reductions. Tobacco is well identified for its effects as an inducer of CYP1A2 enzyme. In a COVID+ patient, the consequences of an abrupt cessation of smoking, particularly related with the appearance of respiratory symptoms (cough, dyspnea), must therefore be anticipated for patients receiving psychotropics metabolized by CYP1A2. Plasma concentrations of these drugs are expected to decrease and can be related to an increase risk of relapse. The symptomatic treatments used in COVID-19 have frequent interactions with the most used psychotropics. If there is no curative treatment for infection to SARS-CoV-2, the interactions of the various molecules currently tested with several classes of psychotropic drugs (antidepressants, antipsychotics) are important to consider because of the risk of changes in cardiac conduction. Specific knowledge on COVID-19 remains poor today, but we must recommend rigor in this context in the use of psychotropic drugs, to avoid adding, in patients suffering from psychiatric disorders, potentially vulnerable in the epidemic context, an iatrogenic risk or loss of efficiency.
Collapse
Affiliation(s)
- H Javelot
- Établissement Public de Santé Alsace Nord, Brumath, France; Laboratoire de toxicologie et pharmacologie neuro-cardiovasculaire, université de Strasbourg, Strasbourg, France.
| | - P-M Llorca
- CHU de Clermont-Ferrand, Clermont-Ferrand, France; Université Clermont Auvergne, Clermont-Ferrand, France
| | - D Drapier
- Pôle hospitalo-universitaire de psychiatrie adulte, centre hospitalier Guillaume-Régnier, Rennes, France; EA 4712, comportements et noyaux gris centraux, université de Rennes 1, Rennes, France
| | - E Fakra
- Pôle universitaire de psychiatrie, CHU de Saint-Étienne, Saint-Étienne, France
| | - C Hingray
- Pôle hospitalo-universitaire de psychiatrie d'adultes du Grand Nancy, centre psychothérapique de Nancy, Laxou, France; Département de neurologie, CHU de Nancy, Nancy, France
| | - G Meyer
- Service de pharmacie, Établissement Public de Santé Alsace Nord, Brumath, France; Service de pharmacie, CHU de Strasbourg, Strasbourg, France
| | - S Dizet
- Service de pharmacie, CHS de Sevrey, Chalon-sur-Saône, France
| | - A Egron
- Service de pharmacie, centre hospitalier de Cadillac, Cadillac, France
| | - C Straczek
- Département de pharmacie, CHU Henri-Mondor, Créteil, France; Institut Mondor de recherche biomédical, Inserm U955, équipe 15 neuropsychiatrie translationnelle, Créteil, France
| | - M Roser
- Institut Mondor de recherche biomédical, Inserm U955, équipe 15 neuropsychiatrie translationnelle, Créteil, France; Service de psychiatrie sectorisée, hôpital Albert-Chenevier, Créteil, France
| | - M Masson
- Nightingale Hospitals-Paris, clinique du Château de Garches, Garches, France; SHU, GHU psychiatrie et neurosciences, Paris, France
| | - R Gaillard
- GHU psychiatrie et neurosciences, université de Paris, Paris, France; Sous-section 49-03, Conseil national des universités (CNU), Paris, France
| | - P Fossati
- Inserm U1127, service de psychiatrie adultes, ICM, groupe hospitalier Pitié-Salpêtrière, Sorbonne université, AP-HP, Paris, France
| | - E Haffen
- CIC-1431 Inserm, service de psychiatrie, CHU de Besançon, Besançon, France; Laboratoire de neurosciences, université de Franche-Comté, Besançon, France
| |
Collapse
|
25
|
O'Shea E, Hopper L, Marques M, Gonçalves-Pereira M, Woods B, Jelley H, Verhey F, Kerpershoek L, Wolfs C, de Vugt M, Stephan A, Bieber A, Meyer G, Wimo A, Michelet M, Selbaek G, Portolani E, Zanetti O, Irving K. A comparison of self and proxy quality of life ratings for people with dementia and their carers: a European prospective cohort study. Aging Ment Health 2020; 24:162-170. [PMID: 30381955 DOI: 10.1080/13607863.2018.1517727] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
Objectives: To identify correlates of self-rated and proxy-rated quality of life (QoL) in people with dementia on (i) a dementia-specific and (ii) a capability-wellbeing QoL measure at baseline and 12-month follow-up, and to consider such factors in the context of QoL intervention development.Method: Prospective clinical and demographic data were collected from 451 community-dwelling dyads (mild-moderate dementia) across eight European countries. QoL was measured using the QOL-AD and the ICECAP-O. Multivariate modelling identified correlates of self- and proxy-rated QoL at baseline and at 12-month follow-up.Results: Carer's proxy-ratings of QoL were significantly lower than self-ratings at all time-points for both measures. Proxy-ratings declined over time, but self-ratings remained stable. Baseline predictors of greater self-rated QoL were education, and greater functional ability and relationship quality. Greater proxy-rated QoL was associated with education and greater functional ability, relationship quality, carer social support and carer QoL, lower carer anxiety/depression and less severe neuropsychiatric symptoms in people with dementia. At follow-up, greater self-rated QoL was predicted by greater functional ability, relationship quality, carer social support and having a spousal carer. Greater proxy-rated QoL at follow-up was associated with the same factors as at baseline; however, the dyad living together was an additional predictive factor.Conclusion: Both proxy-ratings and self-ratings of QoL should be interpreted with caution and in the context of each individual caregiving relationship. Different functional, psychosocial, relational and contextual factors influence self- and proxy-ratings, and both sets of factors should be considered in the context of QoL intervention development for the dyad.
Collapse
Affiliation(s)
- E O'Shea
- School of Nursing and Human Sciences, Dublin City University, Dublin, Ireland
| | - L Hopper
- School of Nursing and Human Sciences, Dublin City University, Dublin, Ireland
| | - M Marques
- CEDOC, Chronic Diseases Research Centre, Nova Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal
| | - M Gonçalves-Pereira
- CEDOC, Chronic Diseases Research Centre, Nova Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal
| | - B Woods
- Dementia Services Development Centre, Bangor University, Bangor, UK
| | - H Jelley
- Dementia Services Development Centre, Bangor University, Bangor, UK
| | - F Verhey
- School for Mental Health and Neuroscience, Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, Maastricht University Medical Center, Maastricht, the Netherlands
| | - L Kerpershoek
- School for Mental Health and Neuroscience, Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, Maastricht University Medical Center, Maastricht, the Netherlands
| | - C Wolfs
- School for Mental Health and Neuroscience, Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, Maastricht University Medical Center, Maastricht, the Netherlands
| | - M de Vugt
- School for Mental Health and Neuroscience, Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, Maastricht University Medical Center, Maastricht, the Netherlands
| | - A Stephan
- Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - A Bieber
- Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - G Meyer
- Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - A Wimo
- Department of Neurobiology, Care sciences and Society, Karolinska Institut, Stockholm, Sweden
| | - M Michelet
- Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway
| | - G Selbaek
- Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway
| | - E Portolani
- Alzheimer's Research Unit-Memory Clinic, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - O Zanetti
- Alzheimer's Research Unit-Memory Clinic, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - K Irving
- School of Nursing and Human Sciences, Dublin City University, Dublin, Ireland
| | | |
Collapse
|
26
|
Mahé I, Meyer G, Sanchez O. [What are the special features of the treatment of venous thromboembolic disease in the course of cancer?]. Rev Mal Respir 2019; 38 Suppl 1:e138-e144. [PMID: 31703829 DOI: 10.1016/j.rmr.2019.05.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- I Mahé
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Université de Paris, Service de médecine interne, AH-HP, hôpital Louis-Mourier, 92700 Colombes, France; Innovations Thérapeutiques en Hémostase, INSERM UMRS 1140, 75006 Paris, France
| | - G Meyer
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Université de Paris, Service de pneumologie et soins intensifs, AH-HP, Hôpital Européen Georges-Pompidou, 75015 Paris, France; INSERM UMRS 970, INSERM CIC 1418, 75015 Paris, France
| | - O Sanchez
- F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Innovations Thérapeutiques en Hémostase, INSERM UMRS 1140, 75006 Paris, France; Université de Paris, Service de pneumologie et soins intensifs, AH-HP, Hôpital Européen Georges-Pompidou, 75015 Paris, France.
| | | |
Collapse
|
27
|
Meyer G, Corrêa R, Martins-Junior H, Silva R, Costa S, Santana M. Tambacus (Colossoma macropomum x Piaractus mesopotamicus) alimentados com rações artesanais de macaxeira e soja. ARCH ZOOTEC 2019. [DOI: 10.21071/az.v68i263.4196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
O uso de rações artesanais é uma das alternativas que vem sendo discutidas para a viabilização da piscicultura familiar na Amazônia. A adoção desta estratégia, no entanto, requer o emprego de critérios para o balanceamento das rações. O objetivo deste estudo foi investigar o desempenho produtivo de tambacus (Colossoma macropomum x Piaractus mesopotamicus) quando alimentados com rações artesanais à base de macaxeira e farelo de soja, bem como avaliar a necessidade de suplementá-las em aminoácidos, energia e macro minerais. Para tanto, 813 juvenis (48,49±4,21 g) foram estocados em 15 tanques de concreto com fundo de terra (48,50±3,61 m2 x 0,8 m) e alimentados com cinco diferentes rações, sendo quatro delas artesanais e isoprotéicas (25% PB), a saber: C1 (macaxeira + farelo de soja + premix; como controle), R1 (C1 + fosfato bicálcico), R2 (C1 + fosfato bicálcico + óleo de soja), R3 (C1 + fosfato bicálcico + óleo de soja + DL-metionina) e C2 (ração comercial extrusada 32%PB; utilizada como parâmetro de comparação regional). Após 75 dias, foi detectado o efeito positivo (P
Collapse
|
28
|
Férec S, Drevin G, Palayer M, Legeay M, Meyer G, Deguigne M, Touré A, Compagnon P, Abbara C, Briet M, Lelievre B. Après les mules, les espadrilles…. Toxicologie Analytique et Clinique 2019. [DOI: 10.1016/j.toxac.2019.03.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
29
|
Sanchez O, Benhamou Y, Bertoletti L, Constant J, Couturaud F, Delluc A, Elias A, Fischer AM, Frappé P, Gendron N, Girard P, Godier A, Gut-Gobert C, Laporte S, Mahé I, Mauge L, Meneveau N, Meyer G, Mismetti P, Parent F, Pernod G, Quéré I, Revel MP, Roy PM, Salaün PY, Smadja DM, Sevestre MA. [Recommendations of good practice for the management of thromboembolic venous disease in adults. Short version]. Rev Mal Respir 2019; 36:249-283. [PMID: 30799126 DOI: 10.1016/j.rmr.2019.01.003] [Citation(s) in RCA: 57] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- O Sanchez
- INSERM UMRS 1140, Université Paris Descartes, Sorbonne Paris Cité, Service de Pneumologie et de soins intensifs, hôpital Européen Georges-Pompidou, Assistance publique des Hôpitaux de Paris, 75015 Paris, France; F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France.
| | - Y Benhamou
- Normandie université UNI Rouen U1096, service de médecine interne, CHU Charles Nicolle, 76000 Rouen, France
| | - L Bertoletti
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; INSERM UMR1059, Équipe dysfonction vasculaire et hémostase, service de médecine vasculaire et thérapeutique, CHU de St-Étienne, Université Jean-Monnet, INSERM, CIC-1408, 42000 Saint-Étienne, France
| | - J Constant
- Service de médecine vasculaire, hôpital St-André, université de Bordeaux, 33000 Bordeaux, France
| | - F Couturaud
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; Département de médecine interne et pneumologie, EA3878-GETBO, CIC_INSERM1412, université de Bretagne occidentale, centre hospitalo-universitaire de Brest, 29200 Brest, France
| | - A Delluc
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; EA 3878 GETBO, université de Bretagne occidentale, 29200 Brest, France
| | - A Elias
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; Département de médecine vasculaire, hôpital Sainte-Musse, 83100 Toulon, France
| | - A-M Fischer
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; Université Paris Descartes, Sorbonne Paris Cité, service d'hématologie biologique hôpital Européen Georges-Pompidou, Assistance publique des Hôpitaux de Paris, 75015 Paris, France
| | - P Frappé
- Inserm UMR 1059 Sainbiose DVH, Inserm CIC-EC 1408, département de médecine générale, université de Saint-Étienne, 42000 St-Étienne, France
| | - N Gendron
- INSERM UMR 1148, Université Paris Diderot, Sorbonne Paris Cité, laboratoire d'hématologie, hôpital Bichat-Claude Bernard, AP-HP, 75018 Paris, France
| | - P Girard
- Institut du Thorax-Curie-Montsouris, l'institut Mutualiste Montsouris, 75014 Paris, France
| | - A Godier
- INSERM UMRS 1140, service d'anesthésie réanimation, hôpital Européen Georges-Pompidou, AP-HP, 75015 Paris, France
| | - C Gut-Gobert
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; Département de médecine interne et pneumologie, EA3878-GETBO, CIC_INSERM1412, université de Bretagne occidentale, centre hospitalo-universitaire de Brest, 29200 Brest, France
| | - S Laporte
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; INSERM, unité de Recherche Clinique, SAINBOIS U1059 équipe DVH, université Jean-Monnet, université de Lyon, Innovation, Pharmacologie, CHU Saint-Étienne, hôpital Nord, 42000 Saint-Étienne, France
| | - I Mahé
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; Université Paris 7, Service de Médecine Interne-Hôpital Louis-Mourier, Assistance Publique des Hôpitaux de Paris, 92700 Colombes, France; Inserm UMR_S1140, 75006 Paris, France
| | - L Mauge
- UMR-S 970, PARCC (Paris-Cardiovascular Research Center), Université Paris Descartes, Sorbonne Paris Cité, Service d'Hématologie biologique, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, 75015 Paris, France
| | - N Meneveau
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; Service de cardiologie, CHU Jean Minjoz Boulevard Fleming ; EA3920, Université de Bourgogne-Franche Comté, 25030 Besançon cedex, France
| | - G Meyer
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; INSERM UMRS 970 ; INSERM CIC 1418, université Paris Descartes, Sorbonne Paris Cité, service de pneumologie et de soins intensifs, hôpital Européen Georges-Pompidou, Assistance publique des Hôpitaux de Paris, 75015 Paris, France
| | - P Mismetti
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; INSERM, SAINBOIS U1059 équipe DVH, université Jean-Monnet, université de Lyon, Unité de Recherche Clinique, Innovation, Pharmacologie, et service de médecine vasculaire et thérapeutique, CHU Saint-Étienne, Hôpital Nord, 42000 Saint-Étienne, France
| | - F Parent
- Université Paris-Sud, faculté de médecine, université Paris-Saclay, service de pneumologie, centre de référence de l'hypertension pulmonaire, hôpital Bicêtre, AP-HP, 94270 Le Kremlin Bicêtre, France; INSERM UMR_S 999, hôpital Marie-Lannelongue, 92350 Le Plessis Robinson, France
| | - G Pernod
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; Service universitaire de médecine vasculaire, CHU Grenoble, université Grenoble Alpes CNRS/TIMC-IMAG UMR 5525/Thèmas, 38700 La Tronche, France
| | - I Quéré
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; Département de médecine vasculaire, centre de référence des maladies vasculaires rares, EA2992, université de Montpellier, CHU Montpellier, hôpital Saint-Éloi, 34295 Montpellier cedex 5, France
| | - M-P Revel
- Université Paris Descartes, Sorbonne Paris Cité, service de radiologie A, hôpital Cochin, Assistance publique des Hôpitaux de Paris, 75014 Paris, France
| | - P-M Roy
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; Département de médecine d'urgence et service de médecine vasculaire, CHU Angers, 49000 Angers, France; Institut Mitovasc, UMR 1083, UFR Santé, université d'Angers, 49000 Angers, France
| | - P-Y Salaün
- INSERM EA3878 (GETBO), service de médecine nucléaire, CHRU de BREST, université de Bretagne occidentale, 29200 Brest, France
| | - D M Smadja
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; INSERM UMR-S1140, université Paris Descartes, Sorbonne Paris Cité, hôpital Européen Georges-Pompidou, service d'hématologie, AP-HP, hôpital Européen Georges-Pompidou, laboratoire de recherche biochirurgicale, Fondation Carpentier, 75015 Paris, France
| | - M-A Sevestre
- F-CRIN INNOVTE, 42055 St-Étienne cedex 2, France; Service de médecine vasculaire, EA 7516 Chimère, CHU Amiens, 80080 Amiens, France
| |
Collapse
|
30
|
Delhumau S, Le Roux G, Meyer G, Touré A, Brunet M, Deguigne M. Surdosage en valpromide : comment interpréter le dosage plasmatique de l’acide valproïque ? Toxicologie Analytique et Clinique 2018. [DOI: 10.1016/j.toxac.2018.07.109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
31
|
Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O'Connell C, Carrier M. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16:1891-1894. [PMID: 30027649 DOI: 10.1111/jth.14219] [Citation(s) in RCA: 262] [Impact Index Per Article: 43.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Indexed: 01/03/2023]
Affiliation(s)
- A A Khorana
- Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - S Noble
- Marie Curie Palliative Care Research Centre, Cardiff University, Cardiff, UK
| | - A Y Y Lee
- Department of Medicine, University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - G Soff
- Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - G Meyer
- Department of Respiratory Disease, Hopital Europeen Georges Pompidou, AP-HP, INSERM CIC1418 and Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - C O'Connell
- Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
| | - M Carrier
- Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, Ontario, Canada
| |
Collapse
|
32
|
Philippot Q, Roche A, Goyard C, Pastré J, Planquette B, Meyer G, Sanchez O. Prise en charge de l'embolie pulmonaire grave en réanimation. Méd Intensive Réa 2018. [DOI: 10.3166/rea-2018-0037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
L'embolie pulmonaire (EP) grave, définie par la présence d’un état de choc, est à l'origine d'une mortalité importante. L'objectif de cette mise au point est de synthétiser les dernières avancées et recommandations concernant la prise en charge des formes graves d'EP. La stratification du risque individuel de mortalité précoce permet d'apporter une stratégie diagnostique et thérapeutique optimisée pour chaque patient. Le traitement symptomatique consiste essentiellement en la prise en charge de l'état de choc. L'anticoagulation curative par héparine non fractionnée est réservée aux patients hémodynamiquement instables. Chez ces patients à haut risque, la thrombolyse systémique diminue la mortalité et le risque de récidive d'EP. Chez les patients à risque intermédiaire élevé, la thrombolyse systémique à dose standard diminue le risque de choc secondaire mais sans impact sur la mortalité globale. La thrombolyse est donc réservée aux patients à risque intermédiaire élevé présentant secondairement un état de choc. L'embolectomie chirurgicale reste indiquée en cas de contre-indication absolue à la thrombolyse ou en cas d'échec de celle-ci. Le positionnement dans l'algorithme thérapeutique de l'assistance extracorporelle et des techniques percutanées de revascularisation reste à définir. Leurs indications doivent donc être discutées dans des centres experts après une concertation multidisciplinaire incluant pneumologues, cardiologues, réanimateurs, radiologues interventionnels et chirurgiens cardiaques.
Collapse
|
33
|
Kresoja KP, Meneveau N, Jimenez D, Sanchez O, Becattini C, Spillmann F, Sobkowicz B, Vanni S, Konstantinides S, Kurzyna M, Pruszczyk P, Wilkens H, Bova C, Meyer G, Lankeit M. 2163Predicting in-hospital major bleeding in pulmonary embolism patients treated with systemic thrombolytic therapy. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.2163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- K.-P Kresoja
- Charite - Campus Virchow-Klinikum (CVK), Cardiology, Berlin, Germany
| | - N Meneveau
- University Hospital Besancon, Department of Cardiology,, Besancon, France
| | - D Jimenez
- University Hospital del Henares, Respiratory Department, Instituto Ramόn y Cajal de Investigaciόn Sanitaria IRYCIS, Madrid, Spain
| | - O Sanchez
- University Paris-Descartes, Service de Pneumologie et de Soins Intensifs, Paris, France
| | - C Becattini
- University of Perugia, Medicina Interna e Cardiovascolare, Stroke Unit, Perugia, Italy
| | - F Spillmann
- Charite - Campus Virchow-Klinikum (CVK), Cardiology, Berlin, Germany
| | - B Sobkowicz
- Medical University of Bialystok, Department of Cardiology, Medical University of Bialystok, Bialystok, Poland
| | - S Vanni
- Careggi University Hospital (AOUC), Emergency Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | | | - M Kurzyna
- European Health Center, Department of Pulmonary Circulation and Thromboembolic Diseases, The Medical Centre of Postgraduate, Otwock, Poland
| | - P Pruszczyk
- Medical University of Warsaw, Department of Internal Medicine and Cardiology, Warsaw, Poland
| | - H Wilkens
- Saarland University Hospital, Pneumology, Homburg, Germany
| | - C Bova
- Ospedale SS Annunziata, Department of Medicine, Cosenza, Italy
| | - G Meyer
- Hôpital Européen Georges Pompidou, Université Paris Descartes, Dept of Respiratory Diseases, Paris, France
| | - M Lankeit
- Charite - Campus Virchow-Klinikum (CVK), Cardiology, Berlin, Germany
| |
Collapse
|
34
|
Meyer G, Brenot F, Pacouret G, Simonneau G, Juvin KG, Charbonnier B, Sors H. Subcutaneous Low-Molecular-Weight Heparin Fragmin Versus Intravenous Unfractionated Heparin in the Treatment of Acute Non Massive Pulmonary Embolism: An Open Randomized Pilot Study. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1649960] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryLow-molecular-weight heparins have been extensively investigated in the treatment of deep venous thrombosis but limited data are available concerning their use in pulmonary embolism. In an open, pilot, randomized study, we compare the safety and efficacy of Fragmin, a low-molecular-weight heparin with those of unfractionated heparin in 60 patients with non massive pulmonary embolism (Miller Index < 20). Thirty one patients received unfractionated heparin intravenously and 29 received a fixed dose of 120 Anti-Xa IU/kg of Fragmin administered subcutaneously twice a day for 10 days. There was no pulmonary embolism recurrence nor major bleeding in either group during the treatment period. The decrease in pulmonary vascular obstruction on perfusion lung scan between day 0 and day 10 was 17 ± 13% in the Fragmin group and 16 ± 13% in the heparin group (NS). These results indicate that Fragmin may be a safe and effective treatment of submassive pulmonary embolism.
Collapse
Affiliation(s)
- G Meyer
- The Service de Pneumologie et Réanimation, Hôpital Laennec, Paris, France
| | - F Brenot
- The Service de Pneumologie et Réanimation, Hôpital Antoine Béclère, Clamart, France
| | - G Pacouret
- The Service de Cardiologie D, Hôpital Trousseau, Tours, France
| | - G Simonneau
- The Service de Pneumologie et Réanimation, Hôpital Antoine Béclère, Clamart, France
| | - K Gillet Juvin
- The Service de Pneumologie et Réanimation, Hôpital Laennec, Paris, France
| | - B Charbonnier
- The Service de Cardiologie D, Hôpital Trousseau, Tours, France
| | - H Sors
- The Service de Pneumologie et Réanimation, Hôpital Laennec, Paris, France
| |
Collapse
|
35
|
Kamphuisen PW, Lee AYY, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. J Thromb Haemost 2018; 16:1069-1077. [PMID: 29573330 DOI: 10.1111/jth.14007] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Indexed: 12/13/2022]
Abstract
Essentials Cancer patients receiving anticoagulants for venous thromboembolism have an elevated bleeding risk. This secondary analysis of CATCH assessed characteristics of clinically relevant bleeding (CRB). CRB occurs in 15% of cancer patients with thrombosis using therapeutic doses of anticoagulation. After multivariate analysis, risk factors for CRB were age >75 years and intracranial malignancy. SUMMARY Background Cancer patients with acute venous thromboembolism (VTE) receiving anticoagulant treatment have an increased bleeding risk. Objectives We performed a prespecified secondary analysis of the randomized, open-label, Phase III CATCH trial (NCT01130025) to assess the rate and sites of and the risk factors for clinically relevant bleeding (CRB). Patients/Methods Patients with active cancer and acute, symptomatic VTE received either tinzaparin 175 IU kg-1 once daily or warfarin (target International Normalized Ratio [INR] of 2.0-3.0) for 6 months. Fisher's exact test was used to screen prespecified clinical risk factors; those identified as being significantly associated with an increased risk of CRB then underwent competing risk regression analysis of time to first CRB. Results Among 900 randomized patients, 138 (15.3%) had 180 CRB events. CRB occurred in 60 patients (81 events) in the tinzaparin group and in 78 patients (99 events) in the warfarin group (hazard ratio [HR] 0.64; 95% confidence interval [CI] 0.45-0.89). Common bleeding sites were gastrointestinal (36.7%; n = 66), genitourinary (22.8%; n = 41), and nasal (10.0%; n = 18). In multivariate analysis, the risk of CRB increased with age > 75 years (HR 1.83, 95% CI 1.14-2.94) and intracranial malignancy (HR 1.97, 95% CI 1.07-3.62). In the warfarin group, 40.4% of CRB events occurred in patients with with an INR of < 3.0. A lower time in therapeutic range was associated with a higher risk of CRB. Conclusions CRB is a frequent complication in cancer patients with VTE during anticoagulant treatment, and is associated with age > 75 years and intracranial malignancy.
Collapse
Affiliation(s)
- P W Kamphuisen
- Department of Internal Medicine, Tergooi Hospital, Hilversum, the Netherlands
- Department of Vascular Medicine, University Medical Center Groningen, Groningen, the Netherlands
| | - A Y Y Lee
- Division of Hematology, University of British Columbia and British Columbia Cancer Agency, Vancouver, BC, Canada
| | - G Meyer
- Respiratory Department, Georges Pompidou European Hospital, Université Paris Descartes Sorbonne Paris Cité, INSERM UMRS 970, CIC 1418, Paris, France
| | - R Bauersachs
- Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany
- Center for Thrombosis and Hemostasis, University Medical Center, Mainz, Germany
| | | | | | - A A Khorana
- Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
| |
Collapse
|
36
|
Kraaijpoel N, Bleker S, van Es N, Mahé I, Muñoz A, Meyer G, Planquette B, Sanchez O, Bertoletti L, Accassat S, de Magalhaes E, Baars J, Rutten A, Lalezari F, Beyer-Westendorf J, Endig S, Marten S, Porreca E, Rutjes A, Russi I, Constans J, Boulon C, Kleinjan A, Beenen L, Iosub D, Piovella F, Couturaud F, Tromeur C, Biosca M, Assaf J, Helfer H, Pinson M, Lerede T, Falanga A, Lacroix P, Désormais I, Maraveyas A, Bozas G, Aggarwal A, Rickles F, Girard P, Caliandro R, Martinez del Prado P, de Prado Maneiro C, García Escobar I, Gonzàlez Santiago S, Schmidt J, Dublanchet N, Aquilanti S, Confrere E, Paleiron N, Grange C, Sevestre M, Ferrer Pérez A, Salgado Fernández M, Falvo N, Thaler J, Otten H, Carrier M, Bergmann J, Büller H, Di Nisio M. Treatment and long-term clinical outcomes of incidental pulmonary embolism in cancer patients: an international prospective cohort study. Thromb Res 2018. [DOI: 10.1016/j.thromres.2018.02.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
37
|
Kraus A, Penna-Martinez M, Meyer G, Badenhoop K. Impaired Vitamin D metabolism with low IL-6 and CCL-2 responsiveness to in-vitro Vitamin D treatment in autoimmune polyglandular syndrome type 2 (APS-2). DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- A Kraus
- Universitätsklinikum Frankfurt, Medizinische Klinik 1, Molekulare Endokrinologie, Frankfurt am Main, Germany
| | - M Penna-Martinez
- Universitätsklinikum Frankfurt, Medizinische Klinik 1, Molekulare Endokrinologie, Frankfurt am Main, Germany
| | - G Meyer
- Universitätsklinikum Frankfurt, Medizinische Klinik 1, Molekulare Endokrinologie, Frankfurt am Main, Germany
| | - K Badenhoop
- Universitätsklinikum Frankfurt, Medizinische Klinik 1, Molekulare Endokrinologie, Frankfurt am Main, Germany
| |
Collapse
|
38
|
Bolea G, Philouze C, Dubois M, Humberclaude A, Ginies C, Arnaud C, Meyer G, Dufour C. Apple polyphenols decrease endothelial dysfunction and atherosclerosis after chronic Western diet in a ApoE mouse model. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2018.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
39
|
Strock E, Risdon S, Mattia E, Revol C, Battault S, Gayrard S, Walther G, Meyer G. Involvement of sodium-glucose cotransporters in the deleterious effects of acute hyperglycemia on vascular function: Implication of oxidative stress. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2018.02.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
40
|
Decousus H, Bertoletti L, Fournel P, Bourmaud A, Labruyère C, Presles E, Merah A, Laporte S, Stefani L, Landry G, Chauvin F, Meyer G. In patients with cancer, prognostic factors of catheter-related thrombosis (CRT) are different than prognostic factors of VTE. A prospective cohort study in 3032 cancer patients with central venous catheter (ONCOCIP). Thromb Res 2018. [DOI: 10.1016/j.thromres.2018.02.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Kraus AU, Penna-Martinez M, Meyer G, Badenhoop K. Vitamin D effects on monocytes' CCL-2, IL6 and CD14 transcription in Addison's disease and HLA susceptibility. J Steroid Biochem Mol Biol 2018; 177:53-58. [PMID: 28765037 DOI: 10.1016/j.jsbmb.2017.07.026] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Revised: 07/19/2017] [Accepted: 07/20/2017] [Indexed: 12/31/2022]
Abstract
Addison's disease is a rare autoimmune disorder leading to adrenal insufficiency and life-long glucocorticoid dependency. Vitamin D receptor (VDR) polymorphisms and vitamin D deficiency predispose to Addison's disease. Aim of the current study was, to investigate potential anti-inflammatory vitamin D effects on monocytes in Addison's disease, focusing on inflammatory CCL-2 and IL6, as well on monocyte CD14 markers. Addison's disease is genetically linked to distinct HLA susceptibility alleles. Therefore we analyzed, whether HLA genotypes differed for vitamin D effects on monocyte markers. CD14+ monocytes were isolated from Addison's disease patients (AD, n=13) and healthy controls (HC, n=15) and stimulated with 1,25-dihydroxyvitamin D3 and IL1β as an inflammatory stimulant. Cells were processed for mRNA expression of CCL-2, IL6 and CD14 and DNA samples were genotyped for major histocompatibility class (MHC) class II-encoded HLA- DQA1-DQB1 haplotypes. We found a downregulation of CCL-2 after vitamin D treatment in IL1β-stimulated monocytes both from AD patients and HC (AD p<0.001; HC p<0.0001). CD14 expression however, was upregulated in both HC and AD patients after vitamin D treatment (p<0.001, respectively). HC showed higher CD14 transcription level than AD patients after vitamin D treatment (p=0.04). Compared to IL1β-induced inflammation, HC have increased CD14 levels after vitamin D treatment (p<0.001), whereas the IL1β-induced CD14 expression of AD patients' monocytes did not change after vitamin D treatment (p=0.8). AD patients carrying HLA high-risk haplotypes showed an increased CCL-2 expression after IL1β-induced inflammation compared to intermediate-risk HLA carriers (p=0.05). Also HC monocytes' CD14 transcription after IL1β and vitamin D co-stimulation differed according to HLA risk profile. We show that vitamin D can exert anti-inflammatory effects on AD patients' monocytes which may be modulated by HLA risk genotypes.
Collapse
Affiliation(s)
- A U Kraus
- Department of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, University Hospital Frankfurt, Germany.
| | - M Penna-Martinez
- Department of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, University Hospital Frankfurt, Germany
| | - G Meyer
- Department of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, University Hospital Frankfurt, Germany
| | - K Badenhoop
- Department of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, University Hospital Frankfurt, Germany
| |
Collapse
|
42
|
Girard P, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R, Oliviero G, Taillade L, Chouaid C, Giraud F, Falcoz P, Revel M, Westeel V, Dixmier A, Trédaniel J, Dehette S, Decroisette C, Prevost A, Pichon E, Fabre E, Soria J, Friard S, Caliandro R, Jabot L, Dennewald G, Pavy G, Petitpretz P, Tourani J, De Luca K, Jouveshomme S, Jebrak G, Poudenx M, Vaylet F, Igual J, Daniel C, Alifano M, Chatelier G, Meyer G. Effet anti-tumoral d’une héparine de bas poids moléculaire dans le cancer bronchique localisé : l’essai Tinzaparin In Lung Tumors (TILT). Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Moumneh T, Riou J, Friou E, Meyer G, Mottier D, Roy P. Les modèles de risque de maladie thromboembolique veineuse acquise chez les patients hospitalisés en secteur médical. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Besse B, Girard P, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R, Oliviero G, Taillade L, Chouaid C, Giraud F, Falcoz PE, Revel MP, Westeel V, Alifano M, Chatellier G, Meyer G. Antitumoral effect of low molecular weight heparin in localized lung cancer. A randomized phase III controlled trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx669.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, Carrier M. Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2017; 15:2076-2079. [PMID: 28851126 DOI: 10.1111/jth.13791] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Indexed: 08/31/2023]
Affiliation(s)
- A Delluc
- EA 3878, Department of Internal Medicine and Chest Diseases, Centre hospitalier universitaire de Brest, Hôpital de la Cavale Blanche, Brest, France
| | - D Antic
- Clinic for Hematology, Lymphoma Center, Clinical Center Serbia, Medical Faculty, Department for Internal Medicine, University of Belgrade, Belgrade, Serbia
| | - R Lecumberri
- Hematology Service, Clínica Universidad de Navarra, Pamplona, Spain
| | - C Ay
- Department of Medicine I, Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| | - G Meyer
- Department of Respiratory Disease, Hôpital Européen Georges Pompidou, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMRS 970 and CIC 1418, Paris, France
| | - M Carrier
- Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
| |
Collapse
|
46
|
Wüstner A, Luderer C, Kress W, Heller R, Zierz S, Meyer G, Sackmann R, Hoffmann K. P 51 Methods of qualitative research in the analysis of development and care in children with rare diseases. Clin Neurophysiol 2017. [DOI: 10.1016/j.clinph.2017.06.129] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Scotté F, Elalamy I, Mayeur D, Meyer G. Factors influencing the use of thromboprophylaxis in cancer outpatients: CAT AXIS, a case-vignette study on clinical practice. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx388.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Laporte S, Chapelle C, Bertoletti L, Ollier E, Zufferey P, Lega JC, Merah A, Décousus H, Schulman S, Meyer G, Cucherat M, Mismetti P. Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta-analysis of randomized controlled trials. J Thromb Haemost 2017; 15:1547-1558. [PMID: 28544422 DOI: 10.1111/jth.13740] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2016] [Indexed: 01/27/2023]
Abstract
Essentials Surrogacy of clinically relevant bleeding (CRB) for major bleeding has never been validated. Our meta-analysis evaluated CRB surrogacy in trials of new versus traditional anticoagulants. Surrogacy was not validated in orthopedic surgery, venous thromboembolism or atrial fibrillation The difficulty in demonstrating the surrogacy may reflect a lack of homogeneity in its definition SUMMARY: Background Clinically relevant bleeding (CRB), comprising major bleeding and clinically relevant non-major bleeding, has been used as a surrogate for major bleeding in most anticoagulant trials. The validity of this surrogate to estimate trade-off between thrombotic and bleeding events in clinical trials was never assessed. Methods We systematically reviewed randomized phase III trials comparing new anticoagulants with the standard of care for venous thromboembolism prevention following major orthopedic surgery, venous thromboembolism (VTE) treatment, or stroke and systemic embolism prevention in atrial fibrillation (AF), and reporting both major bleeding and CRB rates. The validity of CRB as a surrogate for major bleeding was assessed according to the strength of the association between the relative risks of major bleeding and CRB, measured by the use of R2trial and its 95% confidence interval (CI). Results In the postoperative prophylactic setting (13 studies), major bleeding and CRB rates were 1.12% and 3.56%, respectively, and R2trial was 0.69 (95% CI 0.34-0.93). For acute VTE studies (n = 12), major bleeding and CRB rates were 1.87% and 9.07%; the corresponding R2trial values were 0.28 (95% CI 0.01-0.80) and 0.68 (95% CI 0.09-1.00) when only double-blind studies were considered (n = 7). For AF studies (n = 7; 22 strata), major bleeding and CRB rates were 4.82% and 15.3%, and R2trial was 0.59 (95% CI 0.15-0.82). Conclusion Despite an apparent correlation between CRB and major bleeding in major orthopedic surgery, AF, and double-blind acute VTE studies, the wide CIs suggest that CRB might not be an acceptable surrogate outcome in any of these settings.
Collapse
Affiliation(s)
- S Laporte
- SAINBIOSE U1059, Université Jean Monnet, Université de Lyon, INSERM, Saint-Etienne, France
- Unité de Recherche Clinique, Innovation, Pharmacologie, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne, France
| | - C Chapelle
- Unité de Recherche Clinique, Innovation, Pharmacologie, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne, France
| | - L Bertoletti
- SAINBIOSE U1059, Université Jean Monnet, Université de Lyon, INSERM, Saint-Etienne, France
- Service de Médecine Vasculaire et Thérapeutique, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne, France
| | - E Ollier
- SAINBIOSE U1059, Université Jean Monnet, Université de Lyon, INSERM, Saint-Etienne, France
- Laboratoire de Pharmacologie, Toxicologie et Gaz du sang, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne, France
| | - P Zufferey
- SAINBIOSE U1059, Université Jean Monnet, Université de Lyon, INSERM, Saint-Etienne, France
- Unité de Recherche Clinique Innovation, Pharmacologie, and Service d'Anesthésie Réanimation, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne, France
| | - J-C Lega
- Département de Médecine Interne et Pathologie Vasculaire, Hôpital Lyon Sud, CHU Lyon, Pierre-Bénite, France
- UMR CNRS 5558 Evaluation et Modelisation des Effets Therapeutiques, Université Claude Bernard Lyon 1, Lyon, France
| | - A Merah
- Inserm CIE1408, F-CRIN INNOVTE Network, Paris, France
| | - H Décousus
- Inserm CIE1408, F-CRIN INNOVTE Network, Paris, France
| | - S Schulman
- Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
| | - G Meyer
- Hopital Européen Georges Pompidou, APHP, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMRs 970, CIE1418, F-CRIN INNOVTE Network, Paris, France
| | - M Cucherat
- UMR CNRS 5558 Evaluation et Modelisation des Effets Therapeutiques, Université Claude Bernard Lyon 1, Lyon, France
| | - P Mismetti
- SAINBIOSE U1059, Université Jean Monnet, Université de Lyon, INSERM, Saint-Etienne, France
- Unité de Recherche Clinique, Innovation, Pharmacologie, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne, France
| |
Collapse
|
49
|
|
50
|
Meyer G, Schmitz R, Renom A, Stephan A. HOSPITAL ADMISSIONS OF PERSONS WITH DEMENTIA: RESULTS OF THE EUROPEAN RIGHTTIMEPLACECARE PROJECT. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- G. Meyer
- Institute of Health and Nursing Sciences, Martin-Luther-University Halle-Wittenberg, Medical Faculty, Halle (Saale), Saxony-Anhalt, Germany,
| | - R. Schmitz
- Institute of Health and Nursing Sciences, Martin-Luther-University Halle-Wittenberg, Medical Faculty, Halle (Saale), Saxony-Anhalt, Germany,
| | - A. Renom
- Witten University, Witten, Germany
| | - A. Stephan
- Institute of Health and Nursing Sciences, Martin-Luther-University Halle-Wittenberg, Medical Faculty, Halle (Saale), Saxony-Anhalt, Germany,
| |
Collapse
|